Frank Kung, Ph.D., M.B.A.
Dr. Kung is a founding member of Vivo Ventures, LLC (formerly BioAsia
Investments), a healthcare/biotechnology venture capital management firm
in Palo Alto, California.
Dr. Kung started his career in the biotechnology industry in 1979 when
he joined Cetus Corporation. He later co-founded Cetus Immune
Corporation in 1981, which was acquired by its parent company in 1983.
In 1984 he co-founded Genelabs Technologies, Inc. (NADSAQ: GNLB) where
he served as Chairman and CEO until 1995. During his tenure in Genelabs,
he brought the company public in 1991, and built it to a 175 employee
international biotech company with operations in the United States,
Belgium, Singapore, Switzerland and Taiwan.
Dr. Kung received his B.S. in chemistry from the National Tsing Hua
University in Taiwan, his Ph.D. in molecular biology and M.B.A. from the
University of California, Berkeley. He received the Best Use of
Technology Award from the Governor of California, the Entrepreneur of
the Year Awards from Ernst and Young, and the Asian Business League. He
also served on the board of directors of the Emerging Company Governing
Body of the Biotechnology Industry Organization (BIO); Mt. Jade Science
and Technology Association, West Coast; and the Asian American
Manufacturing Association. He was appointed by the U.S. Secretary of
Health and Human Services as a voting member of the National
Biotechnology Policy Board. Dr. Kung currently serves on the board of
directors of a number of emerging healthcare and biotechnology